Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| A092001 | Alliance | Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A092104 | Alliance | A Randomized Phase 2/3 Study of Olaparib plus Temozolomide versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma after Progression on Prior Chemotherapy | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A092105 | Alliance | Randomized Phase 2 Study of Nivolumab and Ipilimumab with or without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma that have Progressed after Platinum Treatment and Immunotherapy | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A092107 | Alliance | A Randomized Phase 2 Trial with a Safety Lead-In to Evaluate Palbociclib versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A092205 | Alliance | Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A151216 | Alliance | Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A151804 | Alliance | Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events | Adult CIRB - Late Phase Emphasis | Available to Open | |
| A171601 | Alliance | A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer | Cancer Prevention and Control CIRB | Available to Open | |
| A171901 | Alliance | Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist's/Patient's Choice) | Cancer Prevention and Control CIRB | Available to Open | |
| A191402CD | Alliance | Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men | Cancer Prevention and Control CIRB | Completed |